Caris Life Sciences (NASDAQ:CAI) Trading Down 9.8% – Time to Sell?

Caris Life Sciences, Inc. (NASDAQ:CAI) shares fell 9.8% during mid-day trading on Monday . The stock traded as low as $25.30 and last traded at $25.73. 1,122,601 shares changed hands during mid-day trading, a decline of 50% from the average session volume of 2,253,037 shares. The stock had previously closed at $28.51.

Wall Street Analyst Weigh In

CAI has been the subject of a number of research reports. Evercore ISI set a $38.00 target price on Caris Life Sciences in a report on Monday, January 5th. Canaccord Genuity Group lifted their price objective on shares of Caris Life Sciences from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Monday, December 22nd. Weiss Ratings restated a “sell (d)” rating on shares of Caris Life Sciences in a research report on Monday, December 29th. Finally, Wall Street Zen cut shares of Caris Life Sciences from a “buy” rating to a “hold” rating in a report on Saturday, December 6th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Caris Life Sciences currently has an average rating of “Reduce” and a consensus price target of $34.00.

Caris Life Sciences Price Performance

The company has a debt-to-equity ratio of 0.79, a current ratio of 9.93 and a quick ratio of 9.36. The company has a market cap of $7.22 billion and a P/E ratio of -55.65.

Insider Buying and Selling at Caris Life Sciences

In other news, insider Luke Thomas Power sold 62,250 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the completion of the sale, the insider owned 99,571 shares of the company’s stock, valued at approximately $2,646,597.18. This represents a 38.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Institutional Trading of Caris Life Sciences

An institutional investor recently bought a new position in Caris Life Sciences stock. Diversified Trust Co. purchased a new stake in Caris Life Sciences, Inc. (NASDAQ:CAI) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 20,000 shares of the company’s stock, valued at approximately $540,000.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.